The Iowa Board of Pharmacy has filed emergency rule making to schedule as a Schedule V controlled substance any FDA-approved drugs that contain cannabidiol (CBD) derived from cannabis and no more than 0.1 percent tetrahydrocannabinols. This emergency scheduling follows the final order published September 28, 2018 in the Federal Register with identical scheduling action by DEA. DEA scheduling of these products follows the recent Food and Drug Administration approval of Epidiolexยฎ. The Boardโ€™s rule making, effective October 3, 2018, temporarily places this drug into Schedule V of the Iowa Uniform Controlled Substances Act (CSA). As required by Iowa Code, the Board has also filed through the routine rule making process a Notice of Intended action for the same scheduling action for the purpose of seeking public input.